Provided by Tiger Trade Technology Pte. Ltd.

Quince Therapeutics, Inc.

3.90
-0.1100-2.74%
Post-market: 3.83-0.0700-1.79%19:56 EST
Volume:927.43K
Turnover:3.51M
Market Cap:217.16M
PE:-3.23
High:4.03
Open:4.00
Low:3.59
Close:4.01
52wk High:4.30
52wk Low:0.7203
Shares:55.68M
Float Shares:49.56M
Volume Ratio:0.59
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2092
EPS(LYR):-1.3136
ROE:-247.78%
ROA:-22.10%
PB:205.06
PE(LYR):-2.97

Loading ...

Company Profile

Company Name:
Quince Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
36
Office Location:
611 Gateway Boulevard,Suite 273,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Directors

Name
Position
Casey C. Lynch
President, Chief Executive Officer and Chairman of the Board
Stephen S. Dominy
Chief Scientific Officer and Director
Christopher J. Senner
Director
David Lamond
Director
Kevin Young
Director
Margi McLoughlin
Director
Una Ryan
Director

Shareholders

Name
Position
Casey C. Lynch
President, Chief Executive Officer and Chairman of the Board
Christopher Lowe
Chief Financial Officer and Treasurer
Kristen Gafric
Senior Vice President, Legal and Administration, and Secretary
Leslie Holsinger
Executive Vice President of Preclinical Development
Michael Detke
Chief Medical Officer
Stephen S. Dominy
Chief Scientific Officer and Director